Atara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Christopher Haqq sold 6,000 shares of the stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $15.30, for a total transaction of $91,800.00. Following the completion of the sale, the executive vice president now directly owns 349,305 shares in the company, valued at $5,344,366.50. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Christopher Haqq also recently made the following trade(s):

  • On Tuesday, August 15th, Christopher Haqq sold 7,604 shares of Atara Biotherapeutics stock. The shares were sold at an average price of $14.75, for a total transaction of $112,159.00.
  • On Monday, July 17th, Christopher Haqq sold 6,000 shares of Atara Biotherapeutics stock. The shares were sold at an average price of $14.92, for a total transaction of $89,520.00.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) traded down 0.96% on Monday, hitting $15.50. 197,930 shares of the company were exchanged. The firm has a 50 day moving average of $14.69 and a 200-day moving average of $15.87. The stock’s market cap is $473.66 million. Atara Biotherapeutics, Inc. has a 52-week low of $11.80 and a 52-week high of $23.00.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.05). On average, equities analysts expect that Atara Biotherapeutics, Inc. will post ($3.89) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Atara Biotherapeutics, Inc. (ATRA) EVP Christopher Haqq Sells 6,000 Shares” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/18/atara-biotherapeutics-inc-atra-evp-christopher-haqq-sells-6000-shares.html.

A number of research firms recently commented on ATRA. Jefferies Group LLC reaffirmed a “buy” rating and issued a $30.00 target price on shares of Atara Biotherapeutics in a research report on Thursday, August 31st. Canaccord Genuity set a $47.00 target price on shares of Atara Biotherapeutics and gave the company a “buy” rating in a research report on Monday, August 7th. ValuEngine raised shares of Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Zacks Investment Research downgraded shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Monday, August 28th. Finally, William Blair reaffirmed an “outperform” rating on shares of Atara Biotherapeutics in a research report on Monday, June 26th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $25.50.

Large investors have recently modified their holdings of the stock. Redmile Group LLC increased its stake in shares of Atara Biotherapeutics by 2.4% in the first quarter. Redmile Group LLC now owns 2,734,118 shares of the biotechnology company’s stock worth $56,186,000 after buying an additional 63,176 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Atara Biotherapeutics by 617.9% in the first quarter. Goldman Sachs Group Inc. now owns 201,214 shares of the biotechnology company’s stock worth $4,135,000 after buying an additional 173,184 shares during the last quarter. American International Group Inc. increased its stake in shares of Atara Biotherapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock worth $294,000 after buying an additional 948 shares during the last quarter. Vident Investment Advisory LLC increased its stake in shares of Atara Biotherapeutics by 20.0% in the first quarter. Vident Investment Advisory LLC now owns 55,665 shares of the biotechnology company’s stock worth $1,144,000 after buying an additional 9,276 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Atara Biotherapeutics in the first quarter worth $132,000. Institutional investors and hedge funds own 82.95% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.